中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2013年
8期
593-596
,共4页
宁海波%刘哲%卢海明%刘雷%李向红%王宪强
寧海波%劉哲%盧海明%劉雷%李嚮紅%王憲彊
저해파%류철%로해명%류뢰%리향홍%왕헌강
外科手术%射频消融%肝癌%门静脉癌栓
外科手術%射頻消融%肝癌%門靜脈癌栓
외과수술%사빈소융%간암%문정맥암전
Surgery%Radiofrequency ablation%Hepatocellular carcinoma%Portal vein tumor thrombus
目的 比较手术切除与射频消融术(RFA)治疗原发性肝癌合并Ⅰ型门静脉癌栓(portal vein tumor thrombus,PVTT)临床效果.方法 回顾分析2006年1月至2009年12月我院收治的30例原发性肝癌合并Ⅰ型门静脉癌栓患者的临床资料.结果 手术切除组(n=15)和射频消融组(n=15)均顺利完成治疗,无围手术期死亡病例.分析显示手术切除和射频消融治疗均能使患者获益.射频消融的疗效与手术切除接近,而且微创安全、并发症少.结论 外科手术切除肝肿瘤病灶+门静脉癌栓取出术以及射频消融术均是治疗原发性肝癌合并Ⅰ型门静脉癌栓的安全、有效的方法,均能改善患者的预后、降低肿瘤的复发.
目的 比較手術切除與射頻消融術(RFA)治療原髮性肝癌閤併Ⅰ型門靜脈癌栓(portal vein tumor thrombus,PVTT)臨床效果.方法 迴顧分析2006年1月至2009年12月我院收治的30例原髮性肝癌閤併Ⅰ型門靜脈癌栓患者的臨床資料.結果 手術切除組(n=15)和射頻消融組(n=15)均順利完成治療,無圍手術期死亡病例.分析顯示手術切除和射頻消融治療均能使患者穫益.射頻消融的療效與手術切除接近,而且微創安全、併髮癥少.結論 外科手術切除肝腫瘤病竈+門靜脈癌栓取齣術以及射頻消融術均是治療原髮性肝癌閤併Ⅰ型門靜脈癌栓的安全、有效的方法,均能改善患者的預後、降低腫瘤的複髮.
목적 비교수술절제여사빈소융술(RFA)치료원발성간암합병Ⅰ형문정맥암전(portal vein tumor thrombus,PVTT)림상효과.방법 회고분석2006년1월지2009년12월아원수치적30례원발성간암합병Ⅰ형문정맥암전환자적림상자료.결과 수술절제조(n=15)화사빈소융조(n=15)균순리완성치료,무위수술기사망병례.분석현시수술절제화사빈소융치료균능사환자획익.사빈소융적료효여수술절제접근,이차미창안전、병발증소.결론 외과수술절제간종류병조+문정맥암전취출술이급사빈소융술균시치료원발성간암합병Ⅰ형문정맥암전적안전、유효적방법,균능개선환자적예후、강저종류적복발.
Objective To compare the results of surgical resection with radiofrequency ablation in the treatment of primary hepatocellular carcinoma with type Ⅰ portal vein tumor thrombus.Methods The clinical data of 30 patients with primary hepatocellular carcinoma with type Ⅰ portal vein tumor thrombus treated between January 2006 and December 2009 were analyzed retrospectively.Patients were divided into two groups according to the treatment.Result The treatments were successfully carried out in the surgical resection group (n=15) and the radiofrequency ablation group (n =15).There was no perioperative death.Both surgical resection and radiofrequency ablation improved the overall survival and recurrence-free survival.The survival outcome of radiofrequency ablation was similar to surgical resection.Conclusion Both surgical resection and radiofrequency ablation were safe and effective for patients with primary hepatocellular carcinoma with type Ⅰ portal vein tumor thrombus and improved the overall survival and recurrence-free survival.